Search
The research identifies a protein called ENPP1 as a potential drug target in the treatment of advanced cancers with chromosome instability.
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
Breast pathologist Edi Brogi explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease.
Meet Emily Herzlin, who teaches mindfulness and meditation at Memorial Sloan Kettering.
Nick Kroll, Seth Meyers, Amy Schumer, John Mulaney, and special guests hosted the one-night-only event, taking the stage to outwit blood cancers and raising a record-breaking $2.3 million to fuel Memorial Sloan Kettering Cancer Center’s mission of ending cancer for life.
The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.
Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients.
At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.
Get to know Marissa Gredler, a postdoctoral fellow in the Sloan Kettering Institute.
An MSK study found a rise in lumpectomies and a decline in mastectomies — reversing a trend that experts say was leading to the overtreatment of breast cancer.